BBI-DSP7888-201G
Total Payments
$107,447
Transactions
8
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $107,447 | 8 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $107,447 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Sumitomo Dainippon Pharma Co., Ltd. | $107,447 | 1 |
Top Doctors Receiving Payments for BBI-DSP7888-201G
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tucson, AZ | $105,847 | 7 |
| Jason Sheehan | Neurological Surgery | Charlottesville, VA | $1,600 | 1 |
Ad
Manufacturing Companies
- Sumitomo Dainippon Pharma Co., Ltd. $107,447
Product Information
- Type Drug
- Total Payments $107,447
- Total Doctors 1
- Transactions 8
About BBI-DSP7888-201G
BBI-DSP7888-201G is a drug associated with $107,447 in payments to 1 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Sumitomo Dainippon Pharma Co., Ltd..
Payment data is available from 2017 to 2017. In 2017, $107,447 was paid across 8 transactions to 1 doctors.
The most common payment nature for BBI-DSP7888-201G is "Unspecified" ($107,447, 100.0% of total).
BBI-DSP7888-201G is associated with 1 research study, including "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors" ($107,447).